Skip to main content
. 2023 May 12;12(4):2005–2021. doi: 10.1007/s40123-023-00715-y

Fig. 4.

Fig. 4

Cost-effectiveness plane comparing incremental cost and effectiveness for RBZ BS TAE with AFL TAE (base case). AFL aflibercept, BS biosimilar, JPY Japanese yen, PSA probabilistic sensitivity analysis, QALYs quality-adjusted life-years, RBZ ranibizumab, TAE treat-and-extend